Ikena Oncology Stock Price To Earnings To Growth
| IKNA Stock | USD 17.16 0.60 3.62% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Ikena Oncology's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Ikena Oncology Company Price To Earnings To Growth Analysis
Ikena Oncology's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Ikena Oncology has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Ikena Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ikena Oncology's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ikena Oncology could also be used in its relative valuation, which is a method of valuing Ikena Oncology by comparing valuation metrics of similar companies.Ikena Oncology is currently under evaluation in price to earnings to growth category among its peers.
Ikena Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 628.86 M | |||
| Shares Outstanding | 41.89 M | |||
| Shares Owned By Insiders | 8.00 % | |||
| Shares Owned By Institutions | 76.20 % | |||
| Number Of Shares Shorted | 168.63 K | |||
| Price To Earning | 3.89 X | |||
| Price To Book | 6.20 X | |||
| Price To Sales | 43.56 X | |||
| Gross Profit | (29.89 M) | |||
| EBITDA | (48.59 M) | |||
| Net Income | (49.23 M) | |||
| Cash And Equivalents | 192.81 M | |||
| Cash Per Share | 5.32 X | |||
| Total Debt | 7.52 M | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 6.98 X | |||
| Book Value Per Share | 28.82 X | |||
| Cash Flow From Operations | (46 M) | |||
| Short Ratio | 0.88 X | |||
| Earnings Per Share | (7.68) X | |||
| Target Price | 276.0 | |||
| Beta | 0.5 | |||
| Market Capitalization | 718.82 M | |||
| Total Asset | 141.51 M | |||
| Retained Earnings | (331.62 M) | |||
| Working Capital | 116.39 M | |||
| Net Asset | 141.51 M |
About Ikena Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ikena Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ikena Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ikena Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.